Akebia Therapeutics (AKBA) Total Current Liabilities: 2016-2025
Historic Total Current Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $133.4 million.
- Akebia Therapeutics' Total Current Liabilities rose 102.98% to $133.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.4 million, marking a year-over-year increase of 102.98%. This contributed to the annual value of $80.9 million for FY2024, which is 18.98% down from last year.
- Per Akebia Therapeutics' latest filing, its Total Current Liabilities stood at $133.4 million for Q3 2025, which was up 12.35% from $118.7 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Total Current Liabilities registered a high of $261.1 million during Q4 2021, and its lowest value of $65.7 million during Q3 2024.
- In the last 3 years, Akebia Therapeutics' Total Current Liabilities had a median value of $91.2 million in 2025 and averaged $93.0 million.
- In the last 5 years, Akebia Therapeutics' Total Current Liabilities slumped by 66.09% in 2023 and then skyrocketed by 102.98% in 2025.
- Over the past 5 years, Akebia Therapeutics' Total Current Liabilities (Quarterly) stood at $261.1 million in 2021, then crashed by 50.38% to $129.5 million in 2022, then fell by 22.90% to $99.9 million in 2023, then fell by 18.98% to $80.9 million in 2024, then spiked by 102.98% to $133.4 million in 2025.
- Its Total Current Liabilities stands at $133.4 million for Q3 2025, versus $118.7 million for Q2 2025 and $91.2 million for Q1 2025.